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Abstract
Distillers’ dried grains with solubles (DDGS) is a low-value agro-industrial by-product, rich in arabinoxylans (AX), which is
produced by commercial distillery and bioethanol plants. In a first approach, we investigated the prebiotic potential of four
fractions comprising arabinoxylan oligosaccharides (AXOS) and xylooligosaccharides (XOS) obtained by enzymatic hydrolysis
of AX fractions derived from DDGS and wet solids (in-process sample of DDGS production process). Anaerobic batch cultures
in controlled pH conditions were used to test the prebiotic activity of the samples. Results did not show significant differences
between the enzymatic treatments used, and all AXOS/XOS were extensively fermented after 24 h. In addition, significant
increases (P < 0.05) in Bifidobacterium and total short-chain fatty acids (SCFAs) were observed after 24 h of fermentation.
Finally, DDGS-derived hydrolysates were separated on an anionic semi-preparative column to prepare AXOS/XOS fractions
with degree of polymerisation (DP) greater than 3. Bifidogenic activity and an increase of SCFAs were again observed after 24 h
of fermentation, although this time, the selectivity was higher and the fermentation slower, suggesting that the fermentation of this
substrate could take place (at least partially) in the distal part of the colon with highly desirable beneficial effects.
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Introduction
Gut microbiota plays an important role in the host physiology.
Imbalances in the microbiome have been associated with dis-
eases such as inflammatory bowel diseases (IBDs), irritable
bowel syndrome (IBS), colorectal cancer or metabolic syn-
drome (Sobhani et al. 2011; Collins 2014; Festi et al. 2014;
Machiels et al. 2014). The composition of the gut microbiota
is strongly influenced by different factors including age, host
genetics, antibiotic use, immunological factors and diet (Biagi
et al. 2010; Zhang et al. 2010; Perez-Cobas et al. 2013; Suzuki
and Worobey 2014). Dietary habit is one of the main factors
contributing to the diversity of the gut microbiota. In this
regard, the consumption of probiotics, prebiotics or the com-
bination of both (synbiotics) is a widely used dietary interven-
tion aimed to beneficially modulate the composition of the
intestinal microbiota for the treatment or prevention of gastro-
intestinal diseases (Wasilewski et al. 2015).
Although both probiotics and prebiotics have high potential
for health enhancement and disease prevention, prebiotics have
an advantage over probiotics in the lack of viability issues
during their commercial storage and gastrointestinal passage.
Prebiotics are defined as “a substrate that is selectively utilized
by host microorganisms conferring a health benefit” (Gibson et
al. 2017). In this regard, the main targeted microorganisms for
prebiotics are Bifidobacterium and Lactobacillus species
(Gibson 2004). Beneficial physiological effects of prebiotics
are associated mainly with the production of short-chain fatty
acids (SCFAs) (LeBlanc et al. 2017; Wong et al. 2006) and
with the immunological activities resulting from microbiota
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modulation in the colon (Klaenhammer et al. 2012).
Galactooligosaccharides (GOS) and inulin-type fructans are
among the most common and extensively studied prebiotics
with well demonstrated bifidogenic effects (Vulevic et al.
2015; Vandeputte et al. 2017; Davis et al. 2011). In the last
decade, there had been a growing interest in the development
of novel prebiotics driven by the increased interest in manage-
ment of human health through nutrition, especially by themod-
ulation of gut microbiota (Biswal et al. 2017). All the studies
carried out on established prebiotics have enabled the better
understanding of mechanisms of action and properties, which
have provided the basis for emerging prebiotics including a
range of plant cell wall polysaccharides (Gullon et al. 2013).
The only currently marketed oligosaccharides that are obtained
from lignocellulosic biomass are xylooligosaccharides (XOS)
(Moniz et al. 2014) with Asian countries being the main pro-
ducers as their market is still small in Europe and the USA.
XOS are mainly obtained by autohydrolysis of xylans,
which consist of a linear backbone of β-(1→ 4) linked xy-
lose. The xylose units can be either unsubstituted or mono- or
di- substituted with α-L-arabinofuranosyl (Araf) residues po-
sitioned on C-(O)-2 and/or C-(O)-3 positions, forming
arabinoxylans (AX) (Saulnier et al. 2007). In addition, xylose
residues can be substituted with glucuronic acid or acetyl
groups, while arabinose residues can be esterified with phe-
nolic acids, notably ferulic acid. AX constitutes the major
polysaccharide in cereal grain cell walls and its hydrolysis
with β-endoxylanase yields a mixture of arabinoxylan oligo-
saccharides (AXOS) and XOS (Saulnier et al. 2007). Several
in vivo and in vitro studies (Francois et al. 2012; Finegold et
al. 2014; Gullon et al. 2014) have determined the prebiotic
potential of AXOS/XOS fractions showing the enrichment of
Bifidobacterium species which have been well documented to
promote a number of health benefits for the host (Picard et al.
2005; Russell et al. 2011). Furthermore, XOS/AXOS possess
some advantages over other prebiotics already established in
the market. For example, XOS exhibit greater resistance to pH
and high temperatures than FOS (Wang et al. 2009) and have
been shown to be effective with a lower daily intake (Singh et
al. 2015).
Distillers’ dried grain with solubles (DDGS) is the main
by-product of bioethanol and distillery plants and is produced
in large amounts annually worldwide. Currently, it is princi-
pally used as nutrient supplement in livestock feed due to its
high content of protein, water-soluble vitamins, and minerals
(Klopfenstein et al. 2008; Schingoethe et al. 2009).
Additionally, DDGS is rich in AX and therefore could be a
valuable feedstock for AXOS production, increasing the eco-
nomic value of the by-product as well as contributing to the
sustainable development of bioethanol and distillery plants.
In a previous study, we (Chatzifragkou et al. 2016) inves-
tigated the extractability of protein fromDDGS and in-process
samples, such as wet solids (WS), in order to establish
potential non-animal feed applications. In the present study,
the solid residue of DDGS and WS samples obtained after
protein extraction were investigated as a suitable substrate
for enzymatic hydrolysis, in order to produce AXOS/XOS.
The generated AXOS/XOS fractions were analysed for prebi-
otic potential, using pH-controlled anaerobic batch fermenta-
tion vessels inoculated with human faecal microbiota to sim-
ulate the distal human colonic region.
Materials and methods
Materials
DDGS and wet solids (WS) were provided by a commercial
distillery plant in UK. The samples were lyophilized in a
VirTis Bench Top (SP Scientific, Gardiner, NY, USA)
freeze-drier for 48 h at − 55 °C and stored at − 20 °C.
Enzymatic production and purification of AXOS/XOS
Deproteinised DDGS and WS (Chatzifragkou et al. 2016)
were used for the enzymatic production of oligosaccharides.
A commercial, food-grade GH11 endoxylanase (17 U/mL,
Depol 761P, Biocatalysts, Cardiff, Wales, UK) was used sole-
ly or in combination with a β-glucanase with feruloyl esterase
side activity, hereafter referred to as FAE (4 U/mL, Depol
740 L, Biocatalysts Cardiff, Wales, UK) for the hydrolysis
of deproteinised DDGS and WS. These were used as sub-
strates for enzymatic hydrolysis in concentrations of 10%
(w/v), incubated at 55 °C for 24 h. Upon completion of the
enzymatic reaction, supernatants were collected by centrifu-
gation and analysed for their carbohydrate content. Total car-
bohydrate content was determined according to (Dubois et al.
1956). The oligosaccharide profile of the hydrolysates was
monitored by high-performance anion-exchange chromatog-
raphy with pulsed amperometric detection (HPAEC-PAD,
Thermo Fisher), on Dionex Carbopac PA1column (10 μm,
4.0 × 250 mm) (Thermo Scientific, Loughborough, UK). A
gradient analysis was carried out using (A) water, (B) 1 M
sodium acetate, and (C) 0.5 M NaOH eluents. Running con-
ditions were 0 min (A 80%, C 20%), 30 min (A 63%, B 17%,
C 20%), 35 min (A 60%, B&C 20%), 40 min (A 57.5%, B
22.5%, C 20%), 41 min (B 80%, C 20%) and 47 min up to
65 min (A 80%, C 20%), at a flow rate of 1 mL/min. Linear
xylooligosaccharides up to DP6 (DP, degree of polymerisa-
tion) were identified using commercially available standards
(Megazyme, Bray, Ireland). Substituted or higher DP oligo-
saccharides were identified according to Kosik et al. (2017),
using wheat flour as substrate. Furthermore, enzymatic hydro-
lysates of DDGS andWSwere fractionated by gel filtration, in
order to generate fractions with oligosaccharides of DP ≥ 3.
Oligosaccharides were separated on Biogel P2 (Biorad,
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Hercules, Ca, USA) column eluted at 3 mL/min with
deionised water (Tzortzis et al. 2005). A description of all
tested DDGS and WS samples is given in Table 1.
Faecal sample preparation
Batch culture fermentations were carried out using fresh faecal
samples provided by three healthy volunteers (one male, two
females; age 24–33 years, omnivores). Donors were free of
known metabolic and gastrointestinal diseases and had not
received any antibiotic or probiotic treatment for at least
6 months prior to the experiment. Faecal samples were col-
lected in sterile plastic containers which were stored in anaer-
obic jars containing AnaeroGen sachets (Oxoid, Basingstoke,
UK). Stool samples were used within 2 h of collection. Faecal
samples were diluted in sterile phosphate-buffered saline
(PBS) and homogenised in filter bags using a stomacher
(Stomacher 400, Seward, Worthing, UK) for 4 min to remove
large particles. Resulting faecal slurries were used to inoculate
the batch culture systems.
In vitro batch cultures
One hundred-millilitre sterile batch fermentation vessels
(50 mL working volume) were aseptically filled with 45 mL
of sterile basal nutrient medium and sparged with O2-free N2
(15 mL/min) overnight to establish anaerobic conditions. The
basal medium (per litre) consisted of 2 g peptone water, 2 g
yeast extract, 0.1 g NaCl, 0.04 g K2HPO4, 0.04 g KH2PO4,
0.01 g MgSO4·7H2O, 0.01 g CaCl·6H2O, 2 g NaHCO3, 2 mL
Tween 80, 0.05 g hemin, 0.01 mL vitamin K1, 0.5 g L-cyste-
ine-HCl, 0.5 g bile salt and 4 mL resazurin solution (0.25 g/L).
The positive control FOS (Orafti® P95, Beneo, Upton upon
Severn, UK) and dried substrates of AXOS/XOS hydrolysates
were added (1% w/v) to the respective fermentation vessels
just before the addition of the faecal slurry. Vessels were in-
cubated at 37 °C using a circulating water bath and the pHwas
controlled between 6.7 and 6.9 using an automated pH con-
troller (Fermac 260, Electrolab, Tewkesbury, UK). Each ves-
sel was inoculated with 5 ml of fresh faecal slurry (1:10, w/w).
Batch cultures were conducted for 24 h, and samples of
3.5 mL were collected from each vessel at 0, 4, 8 and 24 h
for counting of bacterial populations, SCFA analyses and for
determining carbohydrate assimilation profiles during fermen-
tation. In a second stage of the study, in order to test the
prebiotic activity of AXOS with DP ≥ 3, 10-mL minibatch
vessels were used. In this case, samples were collected at time
points of 0, 8 and 24 h, while FOS and a commercial XOS
(Longlive Bio-Technology, Shandong, China) product were
used as positive controls. The fermentations of purified
AXOS with DP ≥ 3 were carried out in duplicate and all the
other fermentations in triplicate with different donors.
Lactate and short-chain fatty acid analysis
Samples (1 mL) taken at each fermentation time point were
centrifuged at 13,000×g for 10min. Supernatants were filtered
through a 0.22-μm Millipore syringe filter (Burlington, MA).
HPLC was performed using an Agilent 1100 series HPLC
(Hewlett–Packard, Agilent, Bracknell, UK) equipped with a
Refractive Index (RI) detector. The ion-exclusion REZEX-
ROA Organic acid column (Phenomenex Inc., Macclesfield,
UK) was maintained at a constant temperature of 85 °C. The
eluent was sulphuric acid in HPLC water (0.0025 mmol/ L),
with a flow rate of 0.5 mL/ min. Calibration curves for lactate,
acetate, formate, propionate and butyrate were accomplished
for SCFA quantification. The mean metabolite concentrations
were expressed as mM.
Flow cytometry-fluorescence in situ hybridization
Collected samples (750 μL) were centrifuged at 10,000×g for
5 min at room temperature. Pellets were fixed for further fluo-
rescence in situ hybridization and kept at − 20 °C. Briefly,
Table 1 Description of enzymatically produced and purified AXOS/XOS
Sample Treatment Composition (%, w/w)
DDGS-Xyl Deproteinised DDGS subjected to enzymatic
hydrolysis with GH11 endoxylanase
Mixture of xylose (47%), XOS (DP2-DP6, 36.3%)
and AXOS (XA3XX, 2.4%)
DDGS-Xyl + FAE Deproteinised DDGS subjected to enzymatic
hydrolysis with GH11 endoxylanase and
feruloyl esterase
Mixture of xylose (33.5%), XOS (DP2-DP6, 46%)
and AXOS (XA3XX, 5.4%)
WS-Xyl Deproteinised wet solids subjected to enzymatic
hydrolysis with GH11 endoxylanase
Mixture of xylose (30%), XOS (DP2-DP6, 41.4%)
and AXOS (XA3XX, 4.5%)
WS_Xyl + FAE Deproteinised wet solids subjected to enzymatic
hydrolysis with GH11 endoxylanase and
feruloyl esterase
Mixture of xylose (31%), XOS (DP2-DP6, 31.3%)
and AXOS (XA3XX, 3.1%)
DDGS AXOS/XOS DP ≥ 3 Deproteinised DDGS subjected to enzymatic
hydrolysis with GH11 endoxylanase and
feruloyl esterase and fractionated by gel filtration
Mixture of XOS (DP3-DP6, 59.3%) and AXOS
(XA3XX, 40.5%)
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after centrifugation pellets were re-suspended in 375 μL of 1×
PBS and 1125.5 μL of cold 4% (w/v) paraformaldehyde.
Suspension was mixed and stored at 4 °C for 4–6 h. After
incubation, samples were washed twice with 1 mL of 1×
PBS. Finally, samples were centrifuged at 10,000×g for
5 min, the supernatant was discarded and the pellet was re-
suspended in 300 μL of 1× PBS and 300 μL of ethanol.
Samples were vortexed and stored at − 20 °C for further anal-
ysis. For Flow-FISH cytometry, the 16S ribosomal RNAmol-
ecule labelled with the fluorescent was used for the enumera-
tion of bacterial groups (Table 2).
Seventy-five-microliter aliquots of the fixed samples were
collected from the fixed cell solutions stored at − 20 °C. The
fixed cells were washed twice with PBS and pre-treated for
10 min with lysozyme at 1 mg/mL. Cells were re-suspended
in 1 mL of hybridization buffer (HB). All hybridizations were
performed in the dark at 35 °C overnight in the hybridization
solution containing the appropriate labelled probe (Table 2).
Cells were centrifuged at 10,000×g for 3 min, re-suspended
in pre-warmed washing buffer and incubated at 37 °C for
20 min to remove non-specific binding of the probe. Finally,
cells were centrifuged at 10,000×g for 3 min and re-suspended
in PBS for flow cytometry analysis.
Statistical studies
Statistical analyses were performed using SPSS for Windows,
version 21 (IBM, Armonk, NY). Univariate analysis of vari-
ance and Tukey’s post hoc test was used to determine signif-
icant changes in the microbiota populations and SCFA con-
centrations at inoculation and subsequent sampling points and
to compare differences in the effects of the different substrates
at the same time point. Differences were considered to be
significant when P < 0.05.
Results
Prebiotic potential of produced AXOS/XOS
hydrolysates
Substrate consumption
Hydrolysates treated only with endoxylanase showed initially
lower amounts of xylose and xylobiose (6.06% ± 4.06 and
2.08 ± 1.41) than samples treated with the combination of
the two enzymes (xylanase and FAE) (15.43 ± 4.74 and
12.16 ± 8.03). Supplemental Table S1 shows the AXOS/
XOS consumption over the course of fermentation by faecal
microbiota. The three donors showed slight variations in mag-
nitude and trends that coincided with higher standard devia-
tions. All substrates were totally consumed between 8 and
24 h of fermentation. Oligosaccharides obtained from
DDGS were almost totally depleted after 8 h of fermentation
in donors 1 and 2 while AXOS/XOS obtained from WS were
consumed slower (between 8 and 24 h of fermentation)
(Fig. 1). In donor 3 (data not shown), all substrates (DDGS
and WS) were almost totally consumed after 8 h of fermenta-
tion. The different assimilation profiles observed among do-
nors and time points agreed with the growth kinetic of total
bacteria. In this regard, the maximum bacterial population was
obtained at 8 h in the case of DDGS substrates and at 24 h with
WS substrates. For donor 3, the maximum bacterial popula-
tion occurred at 8 h for both DDGS- and WS-derived
oligosaccharides.
Table 2 16S rRNA-targeted oligonucleotide probes used in this work
Probe name Sequence (5′ to 3′) Targeted bacterial group References
Non Eub ACTCCTACGGGAGGCAGC Negative control Wallner et al. (1993)
Eub338 GCTGCCTCCCGTAGGAGT Total bacteria Daims et al. (1999)
Eub338II GCAGCCACCCGTAGGTGT Total bacteria Daims et al. (1999)
Eub338III GCTGCCACCCGTAGGTGT Total bacteria Daims et al. (1999)
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. Langendijk et al. (1995)
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus/Enterococcus Harmsen et al. (1999)
Bac303 CCAATGTGGGGGACCTT Bacteroides/Prevotella Manz et al. (1996)
Erec482 GCTTCTTAGTCARGTACCG Eubacterium rectale/Clostridium cocoides
(Clostridium cluster IVXa and IVXb)
Franks et al. (1998)
Rrec584 TCAGACTTGCCGYACCGC Roseburia spp. Walker et al. (2005)
Ato291 GGTCGGTCTCTCAACCC Atopobium cluster Harmsen et al. (2000)
Prop853 ATTGCGTTAACTCCGGCAC Clostridium cluster IX Walker et al. (2005)
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii Devereux et al. (1992)
DSV687 TACGGATTTCACTCCT Desulfovibrio spp. Hold et al. (2003)
Chis150 TTATGCGGTATTAATCTYCCTTT Clostridium histolyticum (Clostridium cluster I and II) Franks et al. (1998)
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Enumeration of specific bacterial populations
Bacterial group counts during the batch cultures fermentations
of the different AXOS substrates are shown in Fig. 2 and
Supplemental Table S2.
Overall, the most notable impact of AXOS/XOS fermenta-
tion on the composition of the faecal microbiota was the pop-
ulation growth of Bifidobacterium. AXOS/XOS utilisation by
faecal microbiota resulted in statistically significant increases
(P < 0.05) in Bifidobacterium counts after 24 h of fermentation
for all AXOS/XOS hydrolysates tested (Fig. 2; Supplemental
Table S2). Specifically increases between 1.3 and 1.7 log were
observed at the end of the fermentation (Fig. 2). In addition,
DDGS hydrolysates treated with xylanase (DDGS-Xyl) and
wet solid hydrolysates generated with xylanase and feruloyl
esterase (WS-Xyl + FAE) also increased significantly
Bifidobacterium populations after 8 h of fermentation.
Populations of Bacteroides-Prevotella (BAC) and propionate
producing bacteria (PROP) were increased by more than 10-
fold between 8 and 24 h of fermentation with all AXOS/XOS
substrates except for DDGS-Xyl + FAE, although significant
differences were only observed whenWS-Xyl + FAEwas used
as substrate. The wet solids hydrolysates also increased the
growth of bacteria detected by Lab158 (Lactobacillus/
Enterococcus group) in more than 10-fold over 24 h fermenta-
tion, but the differences were not significant when compared to
time 0 or the negative control. A significant reduction in the
population ofFaecalibacterium prausnitziiwas detected after 8
and 24 hwhen the FOS (positive control) was used as substrate.
No significant changes were detected in any other enumerated
bacterial populations (Supplemental Table S2).
Organic acid production in faecal batch cultures
The production of SCFAs (acetate, formate, propionate and
butyrate) and lactate determined during the fermentation in
batch cultures. All substrates tested, except DDGS-Xyl +
FAE, significantly increased the total SCFA concentrations
(P < 0.05) after 8 and 24 h of fermentation (Fig. 3). Acetate
was the main SCFA detected during the fermentation of all
tested substrates and its production accounted for approxi-
mately 65% of total SCFAs. Significant increases in acetate
(P < 0.05) were also observed at 8 and 24 h of fermentation
with the AXOS substrates, except for DDGS-Xyl + FAE (P =
0.06). A significant increase in lactate was also observed at 8 h
of fermentation with all substrates except in WS-Xyl
(Supplemental Table S3). During the period 8–24 h, lactate
was significantly depleted which is consistent with the fact
that this product can be utilised by other groups of bacteria
to produce acetate, propionate or butyrate (cross-feeding).
Substantial increases in the concentration of propionate, the
second most abundant SCFA after acetate, and moderate
DDGS-Xyl DDGS-Xyl+FAE WS-Xyl WS-Xyl+FAE
0 h
4 h
8 h
Fig. 1 AXOS/XOS hydrolysates assimilation in pH-controlled batch
cultures for donor 1 at time 0, 4 and 8 h after fermentation. X1, X2, X3,
X4, X5, X6 are xylose, xylobiose and xylotriose, xylotetraose,
xylopentaose and xylohexose respectively. XA3XX is 33-α-L-
arabinofuranosyl-xylotetraose. At 24 h, there was no detectable sugar
remaining in all the culture samples
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increases in butyratewere also observed after 24 h (Supplemental
Table S3) although no significant differences were observed be-
tween the time points because of the variation in responses found
between donors. Similarly, no significant differences were found
in formic production after 24 h of fermentation.
Prebiotic potential of purified AXOS/XOS
Figure 4 shows the carbohydrate profiles from commercial
XOS and purified hydrolysates of AXOS/XOS DP ≥ 3 obtain-
ed from DDGS during fermentation. Commercial XOS were
Fig. 2 Some of the bacterial populations analysed by Flow-FISH in batch
cultures containing different substrates: Error bars indicate SD (n = 3).
Significant differences between substrates at the same time point are
indicated with letters (P < 0.05). Asterisks indicate significantly
different compared to 0 h within the same substrate (P < 0.05). Two-
way ANOVA with Tukey’s post hoc tests were used for the statistical
analysis
Fig. 3 Total SCFAs and acetic concentrations (mM) obtained in pH-
controlled batch cultures at 0, 4, 8 and 24 h of fermentation of different
substrates. Error bars indicate SD (n = 3). Significant differences between
substrates at the same time point are indicated with letters. Asterisks
indicate significantly different compared to 0 h within the same
substrate *P < 0.05; **P < 0.01; ***(P < 0.001). Two-way ANOVA
with Tukey’s post hoc tests were used for the statistical analysis
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more quickly fermented than AXOS/XOSDP ≥ 3 where some
oligosaccharides were still present at 24 h. Overall, both XOS
and AXOS DP ≥ 3 were broken down without increases in
xylose.
Counts of all bacterial groups during the mini-batch cul-
tures are shown in Supplemental Table S4. The most no-
ticeable change in the microbiota composition in the pres-
ence of oligosaccharides was a significant increase of
Bifidobacterium numbers (Fig. 5). While commercial
XOS and FOS resulted in significant increases in
Bifidobacterium at 8 and 24 h of fermentation, the
bifidogenic effect of AXOS fractions DP ≥ 3 was more
gradual (Fig. 5). No significant changes were detected in
any of the other bacterial populations enumerated.
Acetate was the main SCFA detected and represented 60–
65% of total SCFAs. Across all substrates, formate and lactate
were transient metabolites reaching maxima at 8 h (Table 3).
Different profiles of production of butyrate and propionate
were observed between commercial FOS and XOS and
AXOS/XOS DP ≥ 3. FOS and XOS resulted in increases in
butyrate after 24 h which accounted for approximately 12% of
total SCFAs. However, the fermentation of AXOS/XOS DP
≥ 3 resulted in significantly increased production of propio-
nate and reduction of butyrate levels compared to the fermen-
tation of FOS and XOS after 24 h.
Fig. 4 AXOS/XOS fractions (DP ≥ 3) assimilation in pH-controlled
batch cultures immediately after inoculation (time 0 h) and after 8 and
24 h of fermentation. X3, X4, X5 and X6 are xylotriose, xylotetraose,
xylopentaose and xylohexose respectively. XA3XX is 33-α-L-
arabinofuranosyl-xylotetraose
Fig. 5 Bifidobacterium abundance along the fermentation under different
substrates: NC (Negative control), FOS (positive control), commercial
XOS (Longlive Bio-Technology, Shandong, China) and AXOS
fractions DP ≥ 3 obtained from DDGS. Error bars indicate SD (n = 3).
Significant differences between substrates at the same time point are
indicated with letters. Two-way ANOVA with Tukey’s post hoc tests
were used for the statistical analysis
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Discussion
The present study aimed to demonstrate the prebiotic potential
of AXOS/XOS derived from wheat DDGS and in-process
samples on human faecal microbiota.
The main characteristic of a prebiotic compound is to in-
duce a selective stimulation of beneficial bacteria in the colon
microbiota (Gibson et al. 2017). In this regard, the
Bifidobacterium genus is the most frequent target for prebi-
otics. Numerous species of Bifidobacterium have been studied
and demonstrated as probiotic agents. A range of health-
promoting activities have been described for bifidobacteria
in recent years including reduction in serum cholesterol, pre-
vention of colorectal cancer, prevention of infectious diar-
rhoea, modulation of mucosal barrier function and production
of amino acids and vitamins (Xiao et al. 2003; D'Aimmo et al.
2012; Zanotti et al. 2015). This study showed that AXOS
hydrolysates promoted bifidogenic activity during the fermen-
tation of the substrates. Selectivity of AXOS/XOS substrates
for bifidobacteria was observed in the period between 0 and
8 h, where most of the oligosaccharides were consumed.
Moderate increases in other groups of bacteria (Bacteroides-
Prevotella and Clostridium cluster IX) were detected simulta-
neously with the significant bifidogenic effect after 8 h, and it
is notable that several members of these groups of bacteria
have been reported to be able to degrade xylan (Wang et al.
2016; Zhang et al. 2016). However, Bifidobacterium was able
to compete more successfully for XOS/AXOS during the first
8 h, demonstrating faster growth than Bacteroides/Prevotella.
Additionally, the proliferation of the Clostridium cluster IX
after 8 h could also result from cross-feeding using the lactate
and acetate generated by Bifidobacterium. A closer examina-
tion of the samples donor by donor revealed that in general,
the bifidogenic effect was smaller in donor 3. The ability of
Bifidobacterium to grow on XOS is reported to be depended
on the strain (Riviere et al. 2014), and a different composition
of Bifidobacterium in donor 3 could be the responsible factor
of this inter-individual variation.
SCFAs produced during oligosaccharide fermentation by
commensal bacteria in the colon are known to contribute to
multiple benefits to the host (Koh et al. 2016). In this study,
AXOS increased the production of total SCFAs with the
greatest contribution to this increase being the production of
acetate. The significant increases in acetate and lactate at 8 h
could relate to the significant growth of the acetate and lactate
producing Bifidobacterium group. Although not statistically
significant, the increases in butyrate during AXOS fermenta-
tion could be related to the increased abundance of the
Clostridium IX group which includes several butyrate pro-
ducers. This would explain why no increases in butyrate were
observed with the positive control which did not induce the
growth of Clostridium IX group and significantly reduced the
Table 3 SCFAs and lactate
concentrations (mM) obtained at
0, 8 and 24 h of fermentation in
mini-batch cultures. Substrates
utilised were: NC (Negative
control), FOS (positive control),
commercial XOS (Longlive Bio-
Technology, Shandong, China)
and AXOS/XOS fractions DP ≥ 3
Acid Time NC FOS XOS AXOS/XOS DP ≥ 3
Lactic 0 h 3.99 (2.32)a 3.44 (0.45)a 3.65 (0.20)a 4.09 (0.04)a
8 h 12.78 (3.05)a 26.96 (1.16)a 26.58 (12.59)a 12.37 (2.32)a
24 h 5.00 (1.96)a 8.77 (7.99)a 10.16 (9.96)a 9.28 (6.16)a
Formic 0 h 2.75 (1.83)a 2.06 (0.00)a 2.77 (0.64)a 1.77 (0.00)a
8 h 2.05 (2.86)a 12.97 (4.45)a* 18.77 (6.41)a 8.08 (4.95)a
24 h 2.05 (3.02)a 6.20 (6.72)a* 11.95 (6.55)a 0.65 (2.32)a
Acetic 0 h 2.35 (1.32)a 5.80 (6.13)a 5.54 (1.00)a 5.60(0.03)a
8 h 12.77 (2.95)a 66.51 (4.94)b* 68.89 (4.10)b* 32.03 (13.83)ab
24 h 22.67 (2.83)a 69.74 (9.71)b* 72.45 (15.92)b* 59.55(1.94)ab
Propionic 0 h 9.56 (1.95) 6.42 (3.00) 8.30 (1.50) 8.69 (0.06)
8 h 5.02 (3.01)a 9.58 (0.86)a 11.03 (0.68)a 10.59 (0.57)a
24 h 7.64 (3.8)a 10.16 (2.54)ab 9.29 (3.05)a 18.80 (1.21)b*
Butyric 0 h 4.63 (2.12)a 2.88 (3.5)a 0.42 (0.2)a 0.42 (0.1)a
8 h 2.60 (1.75)a 4.77 (2.5)a 4.88 (0.1)a 1.58 (0.1)a
24 h 5.00 (3.1)a 13.37 (4.1)b 13.01 (3.5)b 0.68 (0.3)a
Total SCFAs 0 h 23.27 (5.66)a 20.60 (15.13)a 20.68 (15.13)a 20.87 (0.05)a
8 h 32.99 (17.77)a 120.78 (0.08)bc* 130.14 (4.65)c* 64.12 (21.66)ab
24 h 43.48 (12.27)a 108.25 (0.69)b* 116.86 (12.19)b* 92.68 (0.95)b
Standard deviation is shown in parentheses (n = 3). Two-way ANOVAwith Tukey’s post hoc tests were used for
the statistical analysis. Significant differences (P < 0.05) among treatment at the same time point are indicated
with different letters
*Significant difference from 0 h value (P< 0.05)
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main butyrate producer F. prausnitzii after 24 h. Propionate
was the secondmost abundant SCFA produced; its production
has been reported to be related with the presence of side chains
in xylooligosaccharides (XOS) such as in AXOS (Broekaert et
al. 2011; Gullon et al. 2014) and with increases in the
Bacteroides-Prevotella group (Hughes et al. 2008) and
Clostridium cluster IX.
The enzymatic hydrolysis of DDGS and wet solids by
endoxylanases or by the combination of endoxylanases and
FAE enzymes did not result in marked differences in terms
of prebiotic activity of the hydrolysates. The mixture of
these two enzymes was expected to exert a synergistic ac-
tion on the hemicellulose polymer of DDGS and WS res-
idues, which would in turn improve the solubilisation of
AX as well as release ferulic acid as a high-value co-prod-
uct. However, the combination of enzymes also resulted in
higher amounts of arabinose, xylose (X1) and xylobiose
(X2) compared to the hydrolysates generated only by
endoxylanases. The presence of large amounts of mono-
saccharides and disaccharides in prebiotic products is fre-
quently undesirable since these can be metabolised before
reaching the large intestine and hence reducing their ability
to stimulate the growth and/or activity of health-promoting
bacteria. Therefore, although no statistical differences were
observed in our study between the in vitro prebiotic activ-
ity of the enzyme treatments, a further study was carried
out to purify oligosaccharides of DP ≥ 3 that are expected
to have higher persistence in the intestine. The persistence
of prebiotics in the intestine is one of the main aims for
prebiotic development. Some chronic diseases, such as ul-
cerative colitis and colon cancer, frequently start in the
distal colon where a more proteolytic environment exists
before progressing towards the proximal region, which is
characterised by higher saccharolytic activity (Macfarlane
et al. 1992). Consequently, prebiotics that reach the distal
region of the colon could display an advantage in the pre-
vention of some intestinal diseases. A strategy to achieve
this effect is to increase the molecular weight of the prebi-
otic oligosaccharides. In this regard, AXOS/XOS fractions
with DP ≥ 3 obtained from DDGS showed slower fermen-
tation compared to the commercial XOS and the
unfractionated AXOS/XOS hydrolysates that were totally
depleted after 24 h of fermentation. Commercial XOS are
composed of xylobiose (35%) and 60% total fibre (non-
digestible oligomers; n = 3–6) with xylose backbones.
The removal of xy lob iose and the presence of
arabinoxylans in our DDGS-derived hydrolysate appeared
to positively influence the utilisation of these carbohy-
drates by faecal Bifidobacterium. The slow production of
SCFAs and the slower growth of Bifidobacterium reflect
slower fermentation that could be an indicator of a higher
prebiotic selectivity. The multiple side branches present in
AXOS compared to commercial FOS or XOS could
require more and different enzymes for their hydrolysis,
restricting the fermentation of these substrates to less bac-
terial species. The presence of small amounts of carbohy-
drates not exhaustively fermented at 24 h with AXOS/XOS
DP ≥ 3, suggests the potential increase in the bifidobacteria
population after 24 h. On the other hand, the higher pro-
duction of propionate during fermentation of AXOS DP ≥
3 has been related to the presence of side chains in
xylooligosaccharides (XOS) such as those in AXOS
(Broekaert et al. 2011; Gullon et al. 2014). This increase
of propionate in our study agrees with increases in the
populations of propionate producing bacteria such as
Clostridium cluster IX and Bacteroides.
In summary, DDGS and wet solids obtained from dis-
tillery plants were successfully used as substrates for the
enzymatic production of AXOS/XOS with potential prebi-
otic activity. The in vitro fermentation of AXOS hydroly-
sates showed high stimulatory effect on Bifidobacterium.
Removal of monosaccharides and disaccharides from these
hydrolysates resulted in slower growth of Bifidobacterium
and higher propionate concentration than commercial pre-
biotics such as FOS and XOS. This slower fermentation
could be advantageous allowing at least a proportion of
the AXOS/XOS to reach the distal part of the colon with
beneficial effects on disorders which occur in this region.
AXOS/XOS from DDGS could be a promising option to
other established prebiotics such as FOS due to the low
cost of the material source and easy low-cost extraction
methods. Further studies using gut models and human in-
tervention will be required to confirm the prebiotic efficacy
of AXOS/XOS obtained from DDGS.
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